Pre-earnings brief
Reports
Thu, Nov 5, 2026
Est. EPS
—
Est. revenue
—
Implied move
±0.7%
EPS beat rate
38%
Crinetics Pharmaceuticals, Inc. (CRNX) is a healthcare company focused on developing innovative therapies for endocrine diseases. With a market cap of $9 billion, its work in pharmaceuticals is crucial as it addresses unmet medical needs in a specialized area of healthcare.
Last quarter
In Q2 2026, Crinetics reported an EPS of $-1.14, which was better than the expected $-1.23, resulting in a positive surprise of 7.47%. The stock reacted positively, gaining 0.29% the following day.
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-1.40%
Avg 1-day reaction
+1.19%
Overall, expectations for Crinetics' upcoming earnings are cautious, given the lack of analyst estimates and management guidance. Investors will be looking for signs of improvement in EPS and any potential revenue growth.
Bull case
If Crinetics can report an EPS that beats expectations significantly and shows signs of revenue growth, it could lead to a strong positive reaction in the stock.
Bear case
Conversely, if the company reports a larger-than-expected loss or fails to show any revenue growth, it could lead to a negative reaction from investors.
Key metrics to watch
EPS (Earnings Per Share)
$-1.14EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AAlthough specific revenue estimates are not available, any growth in revenue would signal strong demand for their products.
The print will turn on these.
Q1
What will the EPS be for Q3 2026?
Given the company's history of EPS surprises, the actual EPS will be a critical factor in determining market reaction.
Q2
Is there any indication of revenue growth this quarter?
Investors will be looking for signs that the company is gaining traction in its market, which could influence future performance.
Est. EPS
$1.98
Est. Rev
$113.6B
Impl. Move
±4.0%
Why consensus could be wrong
The Street may be underestimating the potential for Crinetics to surprise on the upside with its EPS, given recent positive trends in their product pipeline.
Supporting evidence
The company has shown a pattern of beating EPS estimates in the past quarters.
Options are pricing in a smaller move than historical averages suggest, indicating potential for a larger surprise.
Key risk
If the EPS comes in better than $-1.10, it could shift sentiment significantly.
Pre-commit to what would confirm each case.
The market is debating whether Crinetics can improve its financial performance in a challenging environment.
Bull confirmed if
An EPS of $-1.10 or better would confirm the bull case.
Bear confirmed if
An EPS worse than $-1.20 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±0.73%
Historical Avg
±2.3%
The options market is pricing a relatively small move in the stock, indicating that investors may not expect significant volatility around the earnings report.
Options are pricing ±0.7% while CRNX has averaged ±2.3% over the last 8 prints — setup is pricing cheap.
30d HV
2.1%
Smart-money positioning from the most recent 13F filings.
Institutional
119.21%
of float
Insider
1.13%
of float
Holders
386
institutions
Top Holders· as of Jun 2026
FMR, LLC
15,840,219 sh · $1.3B
14.93%
0.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Crinetics beats expectations, history suggests a potential average move of +1.04%, confirming a bullish outlook.
In line / cautious
If results are in line with expectations, the stock may see muted reactions as investors await further clarity from management.
Miss
If the company misses expectations, history suggests a potential average move of +1.27%, indicating a bearish sentiment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
9,758,938 sh · $829.0M
9.20%
15.1%
Farallon Capital Management LLC
8,989,098 sh · $763.6M
8.47%
7.8%
Wellington Management Group, LLP
7,131,084 sh · $605.8M
6.72%
-12.6%
Driehaus Capital Management, LLC
6,463,551 sh · $549.1M
6.09%
1.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jul 30, 2026 · disclosed Sep 4, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.